We support cellular immune tolerance therapy in Multiple Sclerosis

Multiple Sclerosis (MS) affects 50,000 patients in Spain and 2.5 million in the world. There is currently no cure for this disease.

Thanks to funds from FBLC, the GAEM Foundation has set up antigen-specific therapy with dendritic cells.

Antigen-specific therapy for the treatment of multiple sclerosis (MS) - GAEM Foundation

This is a personalised therapy making it more effective and with fewer risks of side effects for patients with MS and Neuromyelitis Optica (NMO).

Through clinical trials on cell tolerance.